CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of “Buy” from Analysts

Shares of CeriBell (NASDAQ:CBLL) have been given a consensus rating of “Buy” by the seven brokerages that are covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $32.50.

A number of brokerages have recently commented on CBLL. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH initiated coverage on shares of CeriBell in a research note on Friday, April 4th. They set a “buy” rating and a $32.00 target price for the company.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of CeriBell stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the sale, the chief executive officer now directly owns 746,451 shares of the company’s stock, valued at approximately $11,211,694.02. The trade was a 0.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 24,700 shares of company stock valued at $372,434.

Institutional Investors Weigh In On CeriBell

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC bought a new stake in shares of CeriBell during the fourth quarter worth about $128,120,000. TPG GP A LLC bought a new stake in shares of CeriBell during the fourth quarter worth about $102,677,000. Red Tree Management LLC bought a new stake in shares of CeriBell during the fourth quarter worth about $57,083,000. Yu Fan bought a new stake in shares of CeriBell during the fourth quarter worth about $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new position in CeriBell during the fourth quarter worth about $28,160,000.

CeriBell Price Performance

CBLL stock opened at $16.19 on Tuesday. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75. The business has a 50-day moving average of $19.52.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts’ expectations of $17.55 million. As a group, analysts anticipate that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.